Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.24766
Abstract: Key Points Question What is the current rate of adoption of first-line systemic treatment with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) in daily practice? Findings In this cross-sectional study of 282 patients… read more here.
Keywords: metastatic colorectal; colorectal cancer; use perceptions; trends use ... See more keywords
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.52244
Abstract: This comparative effectiveness research study compares outcomes of first-line therapy with immune checkpoint inhibitors vs chemotherapy among patients who have metastatic colorectal cancer with high microsatellite instability, mismatch repair deficiency, and/or high tumor mutational burden. read more here.
Keywords: checkpoint inhibitors; immune checkpoint; metastatic colorectal; inhibitors chemotherapy ... See more keywords
Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.0400
Abstract: This cohort study assesses the clinicopathological features, outcomes, and adverse events of older patients with metastatic colorectal adenocarcinomas. read more here.
Keywords: site mismatch; association survival; mismatch repair; survival metastatic ... See more keywords
Biomarker Testing Disparities in Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.19142
Abstract: This cohort study identifies the factors associated with likelihood of microsatellite instability and KRAS biomarker testing among patients with metastatic colorectal cancer. read more here.
Keywords: colorectal cancer; metastatic colorectal; disparities metastatic; biomarker testing ... See more keywords
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.4465
Abstract: Importance Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer. Objective To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs cetuximab for… read more here.
Keywords: chemotherapy; metastatic colorectal; bevacizumab; colorectal cancer ... See more keywords
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.8196
Abstract: Importance Amplification of ERBB2 (formerly referred to as HER2) is present in nearly 3% of patients with metastatic colorectal cancer overall and 5% of patients with KRAS and NRAS wild-type tumors. Despite the availability of… read more here.
Keywords: erbb2 positive; metastatic colorectal; positive metastatic; colorectal cancer ... See more keywords
Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.1903
Abstract: The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI‐aflibercept in routine clinical practice was… read more here.
Keywords: metastatic colorectal; efficacy safety; colorectal cancer; cancer ... See more keywords
The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4599
Abstract: The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits. Currently, molecular targeting agents and late‐line treatment with regorafenib and trifluridine/tipiracil (FTD/TPI) are available. However, the… read more here.
Keywords: benefit increasing; survival benefit; metastatic colorectal; increasing number ... See more keywords
Cost‐effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.6904
Abstract: Continuation of bevacizumab plus second‐line chemotherapy has significantly improved overall and progression‐free survival in patients with metastatic colorectal cancer (mCRC). However, the cost‐effectiveness of such high cost therapy is still uncertain in China; so this… read more here.
Keywords: colorectal cancer; metastatic colorectal; bevacizumab plus; cost ... See more keywords
A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance
Sign Up to like & getrecommendations! Published in 2024 at "Cell Biochemistry and Function"
DOI: 10.1002/cbf.3906
Abstract: The majority of cancer cases are colorectal cancer, which is also the second largest cause of cancer‐related deaths worldwide. Metastasis is the leading cause of death for patients with colorectal cancer. Metastatic colorectal cancer incidence… read more here.
Keywords: colorectal cancer; cancer; metastatic colorectal; emerging therapies ... See more keywords
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin‐based chemotherapy in patients with metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30880
Abstract: The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin‐induced damage‐repair system. On the basis of prior evidence that the variable… read more here.
Keywords: metastatic colorectal; hic1; tandem repeat; hypermethylated cancer ... See more keywords